Searched for
LUPIN PORTFOLIO
Sunil Singhania-backed Abakkus Flexi Cap Fund increases stake in HDFC Bank, RIL and 29 others in MaySunil Singhania-backed Abakkus Flexi Cap Fund significantly increased its holdings in HDFC Bank and Reliance Industries during May. The fun...- JioBlackRock Flexi Cap Fund exits Adani Enterprises, Adani Ports and 3 other companies; adds Tata Motors and 14 more stocksJioBlackRock Flexi Cap Fund exited Adani Enterprises, Adani Ports and three other stocks in May while adding Tata Motors and 14 new stocks ...
- Capitalmind Flexi Cap Fund adds Nestle India and 10 others, exits SBI and 14 others in MayCapitalmind Flexi Cap Fund made significant portfolio adjustments in May. The fund welcomed Nestle India and eleven new stocks. It also div...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Lupin shares in focus on acquisition of 3 anti-diabetes trademarks to strengthen diabetes portfolioLupin Share Price: Lupin has acquired the anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim to bolster ...
- Fundamental Radar: Sales of this single drug can take Lupin’s US revenue to $1 billion in FY-26Lupin's focus on the US portfolio is to increase dollar sales to above $200 million from the earlier range of $170-190 million. Lupin recen...
- Lupin to resize portfolio, slash costs in US biz turnaroundIn an interview to ET, CEO Vinita Gupta said the company had already exited a few products filed from its Somerset facility in New Jersey a...
- Lupin completes acquisition of portfolio of brands from Anglo-French Drugs & Industries"India is critical in shaping Lupin's growth story going forward. This acquisition strengthens our position in the Indian market, where we ...
- Lupin to acquire Australia-based Southern Cross PharmaGeneric Health, the Australia based wholly-owned subsidiary of Lupin, has entered into a definitive agreement under which Lupin will acquir...
- Lupin launches Methergine brand in US; drugmaker markets five brands in this marketLupin is bolstering its US branded drugs portfolio with the introduction of Methergine, an oral tablet used to treat postpartum haemorrhage...
- Lupin, Boehringer Ingelheim to co-market anti-diabetes drug linagliptin in IndiaBoehringer Ingelheim will continue to sell its linagliptin under the brand names Trajenta (monotherapy) and TrajentaDuo (fixed-dose combina...
- Buyouts unlikely to harm debt-free Lupin's healthWith no new blockbuster drugs going off patent in the near term, generic pharma companies have to explore new areas of growth like specialt...
- Lupin on buying spree; to acquire German company Temmler Pharma's product portfolioA day after announcing its biggest acquisition deal of $880 million, Lupin today said it will buy Germany-based Temmler Pharma's specialty ...
- Lupin signs pact with Onset to sell skin disease lotion in USLupin signed an agreement with Onset Dermatologics under which it will market the latter's skin disease treatment medicine in US market.
- Lupin get the DCGI nod for IVABRADPharmaceutical firm Lupin said it has received the nod of Drug Controller General of India (DCGI) for IVABRAD tablets, used in the treatmen...
Load More
